MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciaf029

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025

Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.

Luetkemeyer Anne F, Chew Kara W, Lacey Stuart, Hughes Michael D, Harrison Linda J, Daar Eric S, Eron Joseph, Fletcher Courtney V, Greninger Alexander L, Hessinger Diane, Li Jonathan Z, Mailhot David, Wohl David, Chayakulkeeree Methee, Mendoza Jose Luis Accini, Elistratova Polina, Makinde Oluwaseun, Morgan Gareth, Portsmouth Simon, Uehara Takeki, Smith Davey, Currier Judith S

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Ensitrelvir, a severe acute respiratory syndrome coronavirus-2 main protease inhibitor, has demonstrated clinical and virologic efficacy in previous studies.

METHODS

In this global phase 3 trial, nonhospitalized adults with mild-to-moderate coronavirus disease 2019 (COVID-19) and symptom onset within 5 days were randomized (1:1) to receive once-daily ensitrelvir (375 mg day 1, 125 mg days 2-5) or blinded matching placebo. The primary endpoint was the restricted mean time to sustained (≥2 days) resolution of 15 COVID-19 symptoms, recorded in participant daily diaries, through day 29 in participants starting treatment within 3 days after symptom onset. Virologic efficacy and safety were assessed.

RESULTS

Of 2093 participants, 1888 started treatment within 3 days after symptom onset. Mean time to symptom resolution was 12.5 and 13.1 days with ensitrelvir and placebo, respectively (difference, -0.6 days; 95% confidence interval, -1.38 to 0.19; P = .14). On day 4, ensitrelvir reduced least-squares mean RNA by 0.72 log10 copies/mL more than placebo (95% confidence interval, 0.55-0.90). Among those with positive viral cultures at enrollment, 274/287 (95.5%) ensitrelvir-treated versus 210/280 (75.0%) placebo-treated participants had negative cultures on day 4. RNA rebound was similar (<1.5%) between groups. The proportion of participants with ≥1 adverse event was similar with ensitrelvir (61.5%) and placebo (60.6%). No treatment-related serious adverse events or deaths occurred. Three (0.3%) ensitrelvir-treated and 1 (0.1%) placebo-treated participants had COVID-19-related hospitalizations by day 29.

CONCLUSIONS

Despite the evidence of antiviral activity with ensitrelvir, this trial did not demonstrate a significant difference in time to sustained symptom resolution.

CLINICAL TRIALS REGISTRATION NUMBER: NCT05305547.

Для цитирования: Luetkemeyer Anne F, Chew Kara W, Lacey Stuart, Hughes Michael D, Harrison Linda J, Daar Eric S, Eron Joseph, Fletcher Courtney V, Greninger Alexander L, Hessinger Diane, Li Jonathan Z, Mailhot David, Wohl David, Chayakulkeeree Methee, Mendoza Jose Luis Accini, Elistratova Polina, Makinde Oluwaseun, Morgan Gareth, Portsmouth Simon, Uehara Takeki, Smith Davey, Currier Judith S. Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025. DOI: 10.1093/cid/ciaf029.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.